Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

Oren Pasvolsky, Liat Shargian, Uri Rozovski, Ofir Wolach, Ron Ram, Michael Y. Shapira, Batia Avni, Polina Stepensky, Moshe Israeli, Liat Vidal-Fisher, Ofer Shpilberg, Pia Raanani, Moshe Yeshurun*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.

Original languageEnglish
Pages (from-to)2747-2754
Number of pages8
JournalLeukemia and Lymphoma
Issue number11
StatePublished - 2021


  • Eltrombopag
  • allogeneic hematopoietic cell transplantation
  • platelet engraftment
  • umbilical cord blood


Dive into the research topics of 'Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation'. Together they form a unique fingerprint.

Cite this